Skip to content

Fighting to Preserve the Benefits of the 340B Program

Facebook page opens in new windowX page opens in new windowLinkedin page opens in new windowMail page opens in new window
RWC-340B
Ryan White Clinics for 340B Access
RWC-340B
  • Members
    • RWC-340B Members
    • Become a Member
  • Benefactors
    • Meet Our Benefactors
    • Benefactor Application
  • Expert Advice
    • Outline of Technical Assistance
    • Peer-to-Peer Mentoring
  • Advocacy
    • Get The Facts
    • TAKE ACTION
    • Congressional Advocacy
    • Regulatory Advocacy
    • State Advocacy
    • Litigation
  • Issues
    • Contract Pharmacy
    • Discriminatory Reimbursement Toolkit
    • Carve-out Toolkit
    • PrEP Toolkit
    • COVID-19 Toolkit
    • RWC-340B Key Research
  • Events
    • Conferences
  • News
  • About Us
    • RWC-340B Principles
  • IRA Resource Center
Search:
  • Members
    • RWC-340B Members
    • Become a Member
  • Benefactors
    • Meet Our Benefactors
    • Benefactor Application
  • Expert Advice
    • Outline of Technical Assistance
    • Peer-to-Peer Mentoring
  • Advocacy
    • Get The Facts
    • TAKE ACTION
    • Congressional Advocacy
    • Regulatory Advocacy
    • State Advocacy
    • Litigation
  • Issues
    • Contract Pharmacy
    • Discriminatory Reimbursement Toolkit
    • Carve-out Toolkit
    • PrEP Toolkit
    • COVID-19 Toolkit
    • RWC-340B Key Research
  • Events
    • Conferences
  • News
  • About Us
    • RWC-340B Principles
  • IRA Resource Center

Alkermes and Viatris Impose 340B Program Contract Pharmacy Restrictions

Drug Pricing, NewsBy RWC-340BJuly 25, 2024

Alkermes and Viatris have become the 36th and 37th manufacturers, respectively, to impose restrictions on contract pharmacy arrangements. These restrictions are effective July 22 and August 1, respectively, but please…

RWC-340B Sends Letter of Support in Whistleblower Suit Alleging Manufacturer Overcharges

Drug Pricing, News, Rulings, RWC-340BBy RWC-340BJanuary 29, 2024

On January 24, 2024, RWC-340B sent a letter of support in connection with a False Claims Act case that, if successful, could clear a pathway for Ryan White clinics (RWCs)…

CMS Defers Decision on Part D 340B Modifier Proposal

Drug Pricing, Medicaid, NewsBy RWC-340BJanuary 5, 2024

CMS published revised guidance on December 14, 2023 to defer its decision to require 340B point-of-sale modifiers for Part D drugs beginning in 2026. RWC-340B submitted comments to CMS’s initial proposal…

FTC Logo

RWC-340B Submits Comments to Federal Trade Commission

Drug Pricing, RegulationsBy RWC-340BApril 22, 2022

As you may know, the Federal Trade Commission recently requested public comments on the impacts of Pharmacy Benefit Managers’ practices, affecting drug affordability and access.   Today, RWC-340B submitted detailed…

Gilead

RWC-340B Sends Letters to Gilead, HHS Secretary, and OPA Director.

Congress, Drug Pricing, HHS, HRSA, Regulations, RWC-340BBy RWC-340BApril 15, 2022

A growing number of pharmaceutical manufacturers have recently posed restrictions affecting Ryan White Clinics and other Safety Net Providers. RWC-340B has taken action to address these challenges head-on.   On…

Johnson Johnson Logo

Johnson & Johnson is the 16th Manufacturer to Restrict Access to 340B Prices at Contract Pharmacies

Congress, Drug Pricing, News, RWC-340BBy RWC-340BMarch 23, 2022

By letter dated March 21, 2021, Johnson & Johnson (J&J) announced that, effective May 2, 2022, it will no longer honor bill-to/ship-to orders for contract pharmacy arrangements with hospitals unless…

RWC 340B Logo hi res 002

RWC-340B Responds to Gilead’s Conditions on 340B Contract Pharmacy

Drug Pricing, RWC-340BBy RWC-340BMarch 17, 2022

As reported today in the 340B Report, Health Care Provider Groups Slam Gilead’s Conditions on 340B Contract Pharmacy (for subscribers only), and RWC-340B President Shannon Stephenson is quoted throughout (excerpt below). Ryan White…

Gilead

Gilead to Restrict Access to 340B Prices at Contract Pharmacies for Branded Hep-C Drugs; AbbVie Adds Imbruvica to Restrictive Contract Pharmacy Policy

Drug Pricing, RWC-340BBy RWC-340BMarch 17, 2022

By letter dated March 15, 2022, Gilead announced that, effective May 2, 2022, it will implement a new “Contract Pharmacy Integrity Initiative” under which it will no longer honor  contract…

Gilead

RWC-340B Sends Gilead Letter Requesting Exceptions for MAP/PAP Policies

Drug Pricing, News, RWC-340BBy RWC-340BMarch 17, 2022

Please see the attached letter to Mr. Charles Clapton, VP of Federal Governmental Affairs with Gilead from RWC-340B President, Shannon Stephenson on behalf of RWC-340B requesting exceptions to MAP/PAP Policies. Should you…

Spanberger

Spanberger to HHS: Hold Drug Companies Accountable for Breaking the Law, Crack Down on Illegal Price Hikes

Drug Pricing, HHS, NewsBy RWC-340BJanuary 26, 2022

In response to a rash of reckless decisions by pharmaceutical companies, U.S. Representative Abigail Spanberger is leading a bipartisan effort to protect the 340B Drug Pricing Program and prevent additional…

←12345…
67891011121314
15→
                                                                            © 2021 Ryan White Clinics for 340B Access. RWC-340B is a 501(c)(4) non-profit corporation.
Go to Top
Translate »